Bristol Myers Squibb (BMY) fell 1.9% to $61.82 on November 3, 2026, giving back its November 2 closing high of $63.02 with no company news to explain it. The weekly uptrend is intact, but the balance of evidence for the next two to six weeks is even, and conviction is low at 1 of 4. The stock lags its sector, sits below the 50-day average, and the nearest upside math is poor.
Why it matters
The news flow around BMY today was constructive but not about BMY. Pfizer raised its full-year revenue guidance to $62-64 billion on demand for non-Covid medicines, as Financial Times News reported. BioNTech lifted its sales outlook to €1.7-1.9 billion, driven by milestone payments from its cancer partnership with Bristol Myers, according to Bloomberg Business. BMY's own third-quarter report is dated October 29, 2026, and Wells Fargo described the results as better than expected. Against that backdrop the stock rose only 1.2% over the past month and 6.3% over six months. Today's drop came on volume about 60% below its 20-day average, so it looks like a quiet slide rather than forced selling. Nothing in the news explains it, and the peer upgrades did not lift the shares.
Over five days the stock gained 0.6% while the S&P 500 (SPY) fell 2.1% and the healthcare sector ETF (XLV) rose 2.8%. The stock therefore held up better than the market but trailed its own sector by 2.3 points. The longer view makes the same point: over 50 days BMY leads the S&P 500 by 0.4% but trails XLV by 7.6%. XLV is up 10.9% over the month and 19.0% year to date, against 14.8% for BMY. The sector is doing the heavy lifting, and BMY is not sharing in it.
The argument about BMY is the familiar one: cheap and well covered, but facing a patent cliff. The positive side says Morningstar sees a wide moat and a dividend payout ratio below 50%, while acknowledging the cliff. Another writer, in NASDAQ Stock Market, cites a 4.2% forward yield and a price below 10 times this year's expected earnings. The cautious side is Wells Fargo, which cut its price target to $60 from $65 and kept an Equal Weight rating over the loss of Eliquis exclusivity in major EU markets. Axios puts the wider problem at more than $500 billion of brand-name sales facing generics between 2026 and 2032, with Eliquis among the biggest.
On valuation, 24 analysts rate the stock a consensus buy, with a mean price target of $65.25, which is 5.3% above the current price. The targets run from $40 to $80, a wide spread that shows how differently analysts value the post-Eliquis earnings base. Wells Fargo's $60 sits just below today's price, while the mean implies modest upside.
What the evidence says
The long-term thesis is intact but in a pause. The price is above its 40-week average and above the 200-day average at $60.01, and the stock is up 14.8% this year. It trades 9.2% below its 52-week high of $68.09 and 35.6% above the low of $45.59. The stock is currently in a pullback inside a larger uptrend. It is below its 10-week average and its 50-day average of $62.61, with the 14-day RSI at 58.7, neither stretched nor oversold.
For the next two to six weeks the balance of evidence is even, and the conviction is low, at 1 of 4 points. Three things drive that. The pullback against the weekly uptrend is not yet stretched, which keeps the longer trend in play. The stock leads the S&P 500 over 50 days. But it lags XLV over the same period, and the shorter-term trend points the other way from the weekly one, so the trend signals do not line up.
The strongest case against an even reading is the positive one. The weekly uptrend is unbroken, the stock has outperformed the market, the consensus rating is buy, and the mean price target is above the price. Yet that case does not tip the balance. The stock has just failed to stay above the 50-day average, it is losing ground to a sector that is surging, and the breakout math below is weak. That mix is why conviction is not higher.
Levels that matter
The structure stays intact above $60.53, a swing zone; the first crack comes on a move below it. The trend itself ends below $60.01, the 200-day average, which is also where the weekly-trend argument is tested. Below that, the next support is $59.06. Those two levels are close together, so the room between a first crack and a broken trend is only about 50 cents.
The breakout level is a daily close above $62.14 on volume above the 20-day average. BMY closed at $63.02 on November 2, above that level, but today's slide put it back beneath. Volume has also been well below average. From $62.14, with a stop at $60.10 (the $60.53 swing zone less a quarter of the 14-day average true range), the first target is the 50-day average at $62.61, which gives 0.2 to 1. The second is the swing zone at $63.16, which gives 0.5 to 1. The math does not reach the 3 to 1 that makes a breakout worth the risk. Only a target near the 52-week high of $68.09 would come close, and the levels in between fall far short.
What would change the picture
A weekly close below $60.01, the 200-day average, would put the long-term uptrend in question and turn the pullback into something larger. The non-price fact that would do the same is evidence that Eliquis erosion in Europe is arriving faster or hitting harder than analysts model. That is exactly the concern behind the Wells Fargo cut.
What to watch
- Earnings: the most recent report is dated October 29, 2026, and the next date is not yet in the data. The number that matters is Eliquis revenue as European exclusivity loss approaches.
- Sector events: peer earnings and guidance, such as Pfizer's raised outlook, move BMY before its own news does. Any further patent-cliff commentary from large drugmakers bears directly on the Eliquis debate.
- Valuation: at $61.82 the stock sits 5.3% below the $65.25 mean price target, inside a $40 to $80 range. A $60 target from Wells Fargo shows how close the cautious view is to the current price.